A Clinical Study of Ifosfamide/Mesna and Cisplatin in Recurrent Epithelial Ovarian Cancer.
- Author:
Jae Ho SHIM
1
;
Kyung Taek JANG
;
Kyung Jun CHOI
;
Hyun Seung KIM
;
Jae Kun SUNWOO
;
Dong Han BAE
Author Information
1. Department of Obstetrics and Gynecology, Chunan Hospital, College of Medicine, Soonchunhyang University, Korea.
- Publication Type:Original Article
- Keywords:
Recurrent epithelial ovarian cancer;
Ifosfomide
- MeSH:
Chungcheongnam-do;
Cisplatin*;
Cyclophosphamide;
Drug Therapy;
Humans;
Middle Aged;
Nausea;
Ovarian Neoplasms*
- From:Korean Journal of Obstetrics and Gynecology
1997;40(11):2500-2505
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
This study was planned to evaluate the efficacy and toxicity of fosfamide/mesna plus cisplatin combined regimen in patients with recurrent and initial therapy-resistant epithelial ovarian cancer. Controversy still remains over the efficacy of cisplatin containing combined chemotherapy as the treatment of recurrent ovarian cancer and refractory to first line chemotherapy. Ifosfamide(isophosphamide) is an analog of cyclophosphamide. It has shown evidences of activity in ovarian cancer and lack of cross-resistance with cyclophosphamide. This study was undertaken for the clinical analysis and evaluation on 16 patients, who were admitted and treated with advanced or recurrent ovarian cancer at the Sooncheunhyang University Chunan Hospital from January 1994 to July 1996. The results were as follows: 1. The mean age of patients was 62 year old with range from 44 to 72. 2. The most frequent side effect was nausea and vomiting(75%), followed by leukocytopenia(68%), alopecia(44%), nephrotoxicity(37%), neurotoxicity(25%), and hepatotoxicity(12%). 3. The mean survival period was 24 months in clinical response cases ranged from 11 months to 36 months, 5 months in progressive cases ranged from 1 month to 14 months. 4. In clinical stages, stage II was 6 cases(37.5%), III was 6 cases(37.5%) and IV was 4 cases(25%). 5. Previously all patients were received debulking surgery and PAC hemotherapy. 6. Overall respons rate was 44%(7/16).
